In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
We compared the in vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium species with a combination of two non-culture-based techniques: the tetrazolium salt 2,3-bis-(2-methoxy-4-nitro-5-[(sulfenylamino)carbonyl]-2H-tetrazolium-hydroxide) (XTT) colorimetric reduction assay, and fluorescent microscopy with the cellular morbidity dye bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC) to directly visualize hyphal damage. Amphotericin B exhibited species-specific concentration-dependent activity, with 50% effective concentrations (EC(50)s) ranging from 0.10 to 0.12 mg/ml for A. fumigatus, 0.36 to 0.53 mg/ml for A. terreus, 0.27 to > or = 32 mg/ml for F. solani, 0.41 to 0.55 mg/ml for F. oxysporum, and 0.97 and 0.65 mg/ml for S. apiospermum and S. prolificans, respectively. Similarly, itraconazole inhibited the growth of A. fumigatus and A. terreus isolates with MICs of <1 mg/ml (EC(50) 0.03 to 0.85 mg/ml) and S. apiospermum, but was not active against Fusarium species or S. prolificans. Voriconazole effectively inhibited the growth of Aspergillus, Fusarium, and S. apiospermum (EC(50) 0.10 to 3.3 mg/ml) but had minimal activity against a multidrug-resistant isolate of F. solani or S. prolificans. Hyphal damage visualized by DiBAC staining was observed more frequently with voriconazole and amphotericin B versus itraconazole. These data highlight the species-specific differences in antifungal pharmacodynamics between mold-active agents that could be relevant for the development of in vitro susceptibility breakpoints and antifungal dosing in vivo.
Lewis
Russell E
RE
University of Houston College of Pharmacy, 1441 Moursund St. #423, Houston, TX 77030, USA. rlewis@uh.edu
Wiederhold
Nathan P
NP
Klepser
Michael E
ME
D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects*; D003124:Colorimetry; D005453:Fluorescence; D005670:Fusarium / Q000187:drug effects*; D017964:Itraconazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D011743:Pyrimidines / Q000494:pharmacology*; D021681:Scedosporium / Q000187:drug effects*; D013045:Species Specificity; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; D000666:Amphotericin B; D065819:Voriconazole
Antimicrob Agents Chemother. 2001 Jan;45(1):124-8
11120954
Antimicrob Agents Chemother. 1998 Nov;42(11):3018-21
9797246
Transpl Infect Dis. 1999 Dec;1(4):247-61
11428996
Clin Infect Dis. 2001 Sep 1;33(5):641-7
11486286
J Clin Microbiol. 2001 Sep;39(9):3402-8
11526191
Clin Microbiol Rev. 2001 Oct;14(4):643-58, table of contents
11585779
Antimicrob Agents Chemother. 2001 Dec;45(12):3474-81
11709327
J Clin Microbiol. 2001 Dec;39(12):4256-63
11724829
Antimicrob Agents Chemother. 2002 Mar;46(3):834-40
11850269
Antimicrob Agents Chemother. 2002 Apr;46(4):1032-7
11897586
Antimicrob Agents Chemother. 2002 Sep;46(9):3001-12
12183260
Clin Infect Dis. 2002 Oct 1;35(7):891-5
12228829
J Clin Microbiol. 2002 Oct;40(10):3776-81
12354880
Infect Dis Clin North Am. 2002 Dec;16(4):915-33, vi-vii
12512187
Clin Infect Dis. 2003 Mar 1;36(5):630-7
12594645
Antimicrob Agents Chemother. 2003 Apr;47(4):1179-86
12654644
Clin Infect Dis. 2003 May 1;36(9):1122-31
12715306
Biochim Biophys Acta. 1979 Jan 11;545(1):46-57
103582
Prog Histochem Cytochem. 1991;24(1):1-86
1712976
Clin Infect Dis. 2001 Feb 1;32(3):358-66
11170942